Ethris Raises $5M in Funding to Advance RNA Therapeutics and Vaccines

Ethris raises $5M in Funding

Ethris (Linkedin), a biotechnology company specializing in RNA therapeutics and vaccines, has secured $5M in funding from the Bill & Melinda Gates Foundation. With a focus on developing innovative therapies using their proprietary RNA and lipidoid nanoparticle technology platform, Ethris aims to address chronic respiratory diseases, emerging respiratory infections, and immuno-modulation through mRNA-based therapies.

Funding Amount: $5 million

Industry: Biotechnology

CEO: Carsten Rudolph (CEO Linkedin)

What Ethris needs to buy: Ethris is seeking research and development partnerships with biotech companies and research institutions to advance their RNA therapeutics and vaccine pipeline. They are also looking for manufacturing and supply chain solutions to optimize the manufacturing process for clinical trials and commercial production. Additionally, Ethris requires support from contract research organizations (CROs) and clinical trial service providers for efficient execution of clinical trials. Companies in the biotech, research, and clinical trial sectors are ideal partners for Ethris to achieve their goals and bring their innovative therapies to market.